Among patients with EGFR-positive NSCLC, 4 of 162 patients (2.5%) with stage IA received adjuvant platinum doublet chemotherapy, which increased to 4 of 90 patients (4.4%) with stage IB, 33 of 62 patients (53.2%) with stage II, and 54 of 74 patients (73.0%) with stage IIIA. This evidence concerns the gene EGFR and non-small cell lung carcinoma.